July 2026 Research Update

This month added a clearer, but still early, signal that some hard-to-treat autoimmune cytopenias that include Evans syndrome can improve quickly when multiple immune-targeting treatments are combined. In a small group of adults treated in routine care, responses were often seen within days and many patients stayed in remission for months, although infections were reported. A separate single-patient report suggests platelet-stimulating treatment may help when low platelets persist in secondary Evans syndrome linked to cancer, but one case cannot show how often this works. [1] [2]

In 22 adults with refractory primary autoimmune cytopenias (including Evans syndrome), a regimen combining a single low dose of daratumumab (an antibody treatment that targets plasma cells), rituximab, and glucocorticoids produced an initial response in 95.5% with a median time to response of 7 days. At a median follow-up of about 10 months, sustained responses were still reported in many patients, and infections were the most common side effect (27.8%), with all adverse events resolving with treatment. Because there was no control group, the study cannot prove how much each drug contributed, but it documents rapid improvements in blood counts in this setting. [1]

In a 66-year-old man with Evans syndrome occurring alongside localized kidney cancer, thrombocytopenia did not resolve after steroids, IVIG, and removal of the kidney tumor, but platelets progressively improved after eltrombopag (a thrombopoietin receptor agonist that stimulates platelet production). The report describes normalization of platelet counts by postoperative week 9 while on eltrombopag, suggesting a possible option for persistent low platelets in some secondary cases. It also underlines that when Evans syndrome appears with another condition, the course may not quickly improve even after the associated condition is treated. [2]

For patients and caregivers, these studies mainly add to the research picture of what has been tried when Evans syndrome is hard to control. The adult cohort suggests that daratumumab plus rituximab and steroids can bring blood counts up quickly for some people, but it also shows that infections can occur and need active management. The cancer-associated case suggests platelet-stimulating therapy may be considered in secondary Evans syndrome with persistent thrombocytopenia, but it is still uncertain how often this helps because it is based on one person. [1] [2]

This month strengthened a consistent message that Evans syndrome in children often travels with broader immune system problems and can signal a more complicated long-term course. Across pediatric cohorts, Evans syndrome showed up frequently among children with autoimmune hemolytic anemia, and it was more common in those with recurrent disease and underlying immune disorders. In a separate long-followed group with persistent antiphospholipid antibodies, Evans syndrome at presentation marked a higher likelihood of later developing clinically classifiable antiphospholipid syndrome and/or lupus. [3] [4]

In a 15-center pediatric cohort of 399 patients with autoimmune hemolytic anemia, Evans syndrome occurred in 37%, and inborn errors of immunity (genetic or functional immune disorders) were identified in 18%. Immune testing was frequently abnormal when it was done, and recurrent autoimmune hemolytic anemia (42%) was more likely in patients who had Evans syndrome, inborn errors of immunity, or other autoimmune diagnoses. Deaths were reported only among patients who had these additional secondary diagnoses, emphasizing that the bigger immune context can matter for outcomes. [3]

In a prospective pediatric cohort of children with persistent antiphospholipid antibodies and blood count problems, about 28% progressed to antiphospholipid syndrome and/or lupus during up to 29 years of follow-up. Evans syndrome at the start was linked to a higher risk of progression compared with isolated thrombocytopenia, and Evans syndrome developing later in follow-up also tracked with progression. The study also noted that lupus anticoagulant was nearly universal in this group, while broader high-risk antibody profiles were more common among those who progressed but were not statistically clear in this small sample. [4]

For families, these studies help clarify that in children, Evans syndrome can sometimes be a sign of a larger immune condition rather than an isolated blood problem. This does not predict what will happen for any one child, but it explains why some children have relapses or develop additional autoimmune diagnoses over time. What remains uncertain is which specific tests best forecast an individual child's path, since immune abnormalities were common but varied, and some antibody patterns did not clearly separate progressors in the smaller cohort. [3] [4]

This month’s case reports showed how Evans syndrome can appear inside a much broader medical situation, where the main challenge is identifying what else is going on and managing complications alongside blood counts. The reports ranged from very early-life onset to pregnancy and later adulthood, and several involved autoimmune diseases or immune suppression. Because each report is one person, they do not show how common these situations are, but they make the range of possible accompanying conditions more concrete. [5] [6] [7] [8] [9]

One newborn case described fetal-onset Evans syndrome with detectable autoantibodies against red blood cells and platelets, later followed by giant cell hepatitis in infancy, with partial improvement after steroids, IVIG, and rituximab but recurrence of hemolysis. In another adult case, Evans syndrome presented severely and later led to the diagnosis of POEMS syndrome, with stabilization after intensive treatment and a plan for autologous stem cell transplantation. Together, these reports highlight that Evans syndrome can sometimes be a clue to a rare underlying immune or blood-related condition, even when early genetic testing is unrevealing. [5] [6]

Two reports centered on Evans syndrome in the setting of systemic lupus erythematosus, showing that overlapping autoimmune processes can complicate the picture. A pregnant 21-year-old with cytopenias improved with steroids and IVIG during pregnancy and had remission after delivery with rituximab and hydroxychloroquine once lupus was diagnosed. Another woman in her early 40s had an overlap of Evans syndrome with thrombotic thrombocytopenic purpura (TTP), and rapid recovery followed plasma exchange with steroids and rituximab, later supported by a finding of severe ADAMTS13 deficiency. [9] [8]

One report described a serious brain abscess caused by Nocardia farcinica in a woman with Evans syndrome who was on immune-suppressing treatment, treated with surgery and long-course antibiotics adjusted for resistance and side effects. Imaging showed near-complete resolution by 6 months and she completed 12 months of therapy without relapse, although medication toxicities occurred and required switching drugs. This case illustrates how infections can become complicated in some immunosuppressed patients, and how treatment may need to be tailored over time. [7]

For patients and caregivers, these case reports mainly matter as real-world examples of why Evans syndrome is sometimes evaluated in a wider context, especially when it starts very early, occurs with pregnancy, or appears alongside other autoimmune symptoms. They also show that complications can come from the underlying immune condition or from immune-suppressing treatment, including rare infections, and that care may involve multiple steps and medication changes. What remains uncertain is how often any specific complication will happen, since each report reflects a single person rather than a group. [5] [6] [7] [8] [9]